Capstone Therapeutics restates Q3 2025 weighted-average shares, lifts loss per share to USD 0.34
CAPS•Q3 2025 EPS restatement
Capstone Therapeutics filed a Form 10-Q/A restating earnings-per-share metrics for the three and nine months ended Sept. 30, 2025.
- Net loss remained unchanged at USD 2.01 million for the quarter, USD 5.15 million for the nine-month period.
- Weighted-average shares rose to 5,838,134 for the quarter, up from 5,700,214 previously reported.
- Nine-month weighted-average shares increased to 4,225,334 from 3,560,035, lifting reported loss per share to USD 1.22 from USD 1.45.
- Management identified a material weakness in controls over weighted-average share calculations; the audit committee concurred the prior EPS figures should not be relied upon.
